Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ

PR Newswire/Les Echos/ 
                          On World Malaria Day 
Sanofi and DNDi celebrate six years of collaboration in fighting malaria by 
              distributing 200 million treatments of ASAQ 
Paris, France, and Geneva, Switzerland - April 25, 2013 - Sanofi (EURONEXT, SAN
and NYSE; SNY) and the Drugs for Neglected Diseases initiative (DNDi), an
independent not-for-profit foundation, announce that on the occasion of World
Malaria Day, more than 200 million treatments of ASAQ Winthrop have been
distributed in Africa since the medication became available in 2007. 
Malaria is the most common and also the most deadly parasitic disease in the
world. According to the World Health Organization (WHO), 219 million cases and
660,000 deaths were reported in 2010, 90% of them in Africa. The impact of
malaria also weighs heavily on the economies of families and the affected
countries. Early diagnosis and treatment of malaria alone would largely help
reduce the intensity of the disease, prevent it from becoming deadly, and 
reduce its transmission. Since 2001, the WHO recommends the use of Artemisinin 
based Combination Therapy: ACT for the treatment of malaria, preferably as 
fixed-dose combinations. 
In a genuine therapeutic and industrial innovation, the un-patented ASAQ
Winthrop(r) treatment combines artesunate and amodiaquine in a fixed-dose
combination, enabling better adherence to treatment and reducing the risk of
resistance development by avoiding selective use of one of the components. 
Developed through an innovative partnership between DNDi and Sanofi, and
manufactured by Sanofi in its Zenata plant in Morocco, ASAQ Winthrop(r) is now
available in most malaria-affected countries, and 90% available in Africa. It 
is easy to use (once-a-day dose) and is available at a price of less than US$1 
for adults and $0.50 for children, for three-day treatment. 
"Above all, this project demonstrates what can be achieved by working together.
Although very different entities, an NGO and a healthcare company worked 
towards the common goal of developing an effective malaria drug to meet the 
needs of the world's poorest populations," said Dr. Bernard Pécoul, Executive 
Director of DNDi. "With the large distribution of ASAQ Winthrop(r) in Africa, 
we are pleased that many patients now have access to this treatment, even in 
the most remote areas." 
ASAQ Winthrop(r) is now available in 32 countries, 30 of them in Africa. The
rapid implementation of ASAQ on the African continent was facilitated by WHO
prequalifying the treatment in 2008 - a first for an ACT. 
"Our Access to Medicines program is designed to tailor our strategy and our
business model to specific markets in which we make neither a loss nor a
profit," said Dr. Robert Sebbag, Vice President, Access to Medicines at Sanofi.
"The treatment itself is only part of the solution; we also need to inform,
communicate, and educate, at every level of the health pyramid from 
specialists, community workers and families to mothers and children." 
ASAQ Winthrop(r) is involved in an unparalleled pharmacovigilance program in
Africa, benefiting from the same standards as those applied in the developed
world for monitoring purposes. Sanofi is also developing training activities 
and educational information on malaria, especially on how it is transmitted and
how it can be prevented in children. Since 2008, the "Schoolchildren against
Malaria" program and its television version helped raise awareness among
approximately three million children in Côte d'Ivoire, Ghana and Burkina Faso.
To participate in the fight against development of resistance to treatment,
Sanofi decided in 2012 to share all the data collected during its clinical
trials with the WWARN (WorldWide Antimalarial Resistance Network). 
About Drugs for Neglected Diseases initiative (DNDi)
DNDi is a not-for-profit research and development (R&D) organization working to
deliver new treatments for the most neglected diseases, in particular sleeping
sickness (human African trypanosomiasis), Chagas disease, leishmaniasis,
filarial infections, and paediatric HIV. Since its inception in 2003, DNDi has
delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ),
nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping
sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy 
for visceral leishmaniasis in Africa, a set of combination therapies for 
visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole 
for Chagas disease. DNDi was established in 2003 by Médecins Sans Frontières 
(MSF), the Indian Council of Medical Research, Brazil's Oswaldo Cruz 
Foundation, the Kenya Medical Research Institute, the Ministry of Health of 
Malaysia, and Institut Pasteur in France, with the UNICEF/UNDP/World Bank/World 
Health Organization's Special Programme for Research and Training in Tropical 
Diseases (TDR) as a permanent observer. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer 
healthcare, emerging markets and animal health. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). 
Contacts :
Sanofi                                 DNDi
Relations Presse                       Relations Presse
Frédéric Lemonde-San                   Violaine Dällenbach
Tél. : + 33 1 53 77 46 46              Tél : +41 22 906 92 47
Mobile : + 33 6 84 06 04 94            Mobile : +41 79 424 14 74
Email :    Email : 
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Apr/25/2013 09:25 GMT